Spotlight On... Celgene buries the hatchet with India's Natco over generic Revlimid; Turing's crisis comms group scrambles; NICE backs Velcade, SGLT2 meds for new uses; Sanofi submits LixiLan to FDA; and more...

Celgene ($CELG) is getting in the holiday spirit, settling its Revlimid patent fight with Indian generics maker Natco. Under the settlement, Celgene will let Natco roll out copycat versions of its $5 billion bestseller starting in 2022, as long as Natco agrees to a "volume-limit license." The license restricts the amount of capsules Natco can sell, giving Celgene some breathing room before Natco's full launch in 2026. More from FiercePharma

> Turing Pharmaceuticals isn't going it alone in the PR battle touched off by pharma bad boy Martin Shkreli, its now-ex-CEO; DCI Group signed on several months ago and is helping manage crisis communications. Report

> U.K. cost-effectiveness watchdogs backed Johnson & Johnson's ($JNJ) Velcade in mantle cell lymphoma, and three SGLT2 diabetes drugs--J&J's Invokana, AstraZeneca's ($AZN) Forxiga and Eli Lilly & Co. ($LLY) and Boehringer Ingelheim's Jardiance--as monotherapies in certain patients. Report

> Sanofi ($SNY) submitted its insulin-plus-GLP-1 diabetes drug LixiLan to the FDA, hoping for an approval next year; one half of that med, the GLP-1 Lyxumia, is awaiting an FDA nod now. Release | More

> Merck KGaA and Pfizer ($PFE) are pushing ahead with two new late-stage studies for avelumab, a PD-L1 cancer med that's playing catch-up in the immuno-oncology field. Report

And Finally... Public health officials are pushing for wider use of a Gilead Sciences ($GILD) drug to prevent HIV infection, but some AIDS groups continue to oppose it. Report